TY - JOUR
T1 - Type i IFN is necessary and sufficient for inflammation-induced red blood cell alloimmunization in mice
AU - Gibb, David R.
AU - Liu, Jingchun
AU - Natarajan, Prabitha
AU - Santhanakrishnan, Manjula
AU - Madrid, David J.
AU - Eisenbarth, Stephanie C.
AU - Zimring, James C.
AU - Iwasaki, Akiko
AU - Hendrickson, Jeanne E.
N1 - Funding Information:
This work was supported by grants from the National Blood Foundation (R13672) (to D.R.G.) and the National Institutes of Health/National Heart, Lung, and Blood Institute (R01 HL126076) (to J.E.H.) and (T32 HL007974-14) (to Brian Smith, Chair of the Department of Laboratory Medicine, Yale University School of Medicine).
Publisher Copyright:
Copyright © 2017 by The American Association of Immunologists, Inc.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - During RBC transfusion, production of alloantibodies against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatible blood products, resulting in anemia-associated morbidity and mortality. Multiple studies have established that certain inflammatory disorders and inflammatory stimuli promote alloimmune responses to RBC Ags. However, the molecular mechanisms underlying these findings are poorly understood. Type I IFNs (IFN-α/β) are induced in inflammatory conditions associated with increased alloimmunization. By developing a new transgenic murine model, we demonstrate that signaling through the IFN-α/β receptor is required for inflammation-induced alloimmunization. Additionally, mitochondrial antiviral signaling protein-mediated signaling through cytosolic pattern recognition receptors was required for polyinosinicpolycytidylic acid-induced IFN-α/β production and alloimmunization. We further report that IFN-α, in the absence of an adjuvant, is sufficient to induce RBC alloimmunization. These findings raise the possibility that patients with IFN-α/β-mediated conditions, including autoimmunity and viral infections, may have an increased risk of RBC alloimmunization and may benefit from personalized transfusion protocols and/or targeted therapies.
AB - During RBC transfusion, production of alloantibodies against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatible blood products, resulting in anemia-associated morbidity and mortality. Multiple studies have established that certain inflammatory disorders and inflammatory stimuli promote alloimmune responses to RBC Ags. However, the molecular mechanisms underlying these findings are poorly understood. Type I IFNs (IFN-α/β) are induced in inflammatory conditions associated with increased alloimmunization. By developing a new transgenic murine model, we demonstrate that signaling through the IFN-α/β receptor is required for inflammation-induced alloimmunization. Additionally, mitochondrial antiviral signaling protein-mediated signaling through cytosolic pattern recognition receptors was required for polyinosinicpolycytidylic acid-induced IFN-α/β production and alloimmunization. We further report that IFN-α, in the absence of an adjuvant, is sufficient to induce RBC alloimmunization. These findings raise the possibility that patients with IFN-α/β-mediated conditions, including autoimmunity and viral infections, may have an increased risk of RBC alloimmunization and may benefit from personalized transfusion protocols and/or targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=85026218383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026218383&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1700401
DO - 10.4049/jimmunol.1700401
M3 - Article
C2 - 28630094
AN - SCOPUS:85026218383
VL - 199
SP - 1041
EP - 1050
JO - Journal of Immunology
JF - Journal of Immunology
SN - 0022-1767
IS - 3
ER -